BI Asset Management Fondsmaeglerselskab A S Sells 16,875 Shares of Amgen Inc. $AMGN

BI Asset Management Fondsmaeglerselskab A S lessened its stake in Amgen Inc. (NASDAQ:AMGN) by 18.1% during the fourth quarter, Holdings Channel reports. The firm owned 76,491 shares of the medical research company’s stock after selling 16,875 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Amgen were worth $25,036,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Dogwood Wealth Management LLC increased its position in shares of Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 55 shares during the last quarter. Anfield Capital Management LLC increased its position in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 70 shares during the last quarter. Board of the Pension Protection Fund purchased a new stake in shares of Amgen during the fourth quarter valued at approximately $26,000. Manning & Napier Advisors LLC increased its position in shares of Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares during the last quarter. Finally, Olistico Wealth LLC purchased a new stake in shares of Amgen during the fourth quarter valued at approximately $33,000. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This represents a 15.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.85% of the stock is owned by insiders.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen received European Commission marketing authorization for IMDYLLTRA® (tarlatamab) as a monotherapy for adults with extensive-stage small cell lung cancer, expanding a key oncology product into the European market and improving the drug’s commercial outlook. Article Title
• Positive Sentiment: Amgen also showed fresh momentum in autoimmune therapies, with new Phase 3 and real-world data on UPLIZNA and TAVNEOS presented at EULAR 2026, which supports the company’s growing presence in high-value specialty medicine niches. Article Title
• Positive Sentiment: One analyst note upgraded Amgen to a cautious Buy, citing improved fundamentals, a diversified pipeline, and growth drivers such as Imdelltra, Uplizna, Tepezza, and Repatha. Article Title

Amgen Trading Up 1.2%

NASDAQ AMGN opened at $349.58 on Friday. The stock has a 50-day moving average of $341.35 and a 200-day moving average of $345.47. The firm has a market cap of $188.67 billion, a PE ratio of 24.33, a price-to-earnings-growth ratio of 3.47 and a beta of 0.42. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. Amgen Inc. has a 1-year low of $267.83 and a 1-year high of $391.29.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, sell-side analysts forecast that Amgen Inc. will post 22.38 EPS for the current year.

Analyst Ratings Changes

AMGN has been the subject of a number of recent research reports. UBS Group raised their target price on Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. The Goldman Sachs Group set a $389.00 target price on Amgen in a research report on Friday. Rothschild & Co Redburn raised their target price on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research report on Wednesday, February 18th. Leerink Partners reissued a “market perform” rating and issued a $355.00 target price on shares of Amgen in a research report on Thursday, March 5th. Finally, Argus reduced their price target on Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, May 20th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $353.81.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.